On 18 December, CHU de Lille and Materia Nova proudly represented the ALCOVE project during an event fully dedicated to capitalisation.
Congratulations to the organisers and speakers for showcasing the impact of cross‑border projects.
PATHACOV ➜ ALCOVE: a natural continuation
The ALCOVE project builds directly on the results of the PATHACOV project, also funded by the Interreg programme, which demonstrated the potential of volatile organic compounds (VOCs) in exhaled breath for lung cancer detection:
identification of a VOC signature in a cohort of 1,500 subjects,
development of a sensor network and dedicated diagnostic algorithms.
ALCOVE now takes this work a step further: validating the effectiveness of the electronic nose in hospital settings, with the goal of making lung cancer screening earlier, more accessible, and better adapted to the needs of the cross‑border territory.
